JP2018537399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537399A5 JP2018537399A5 JP2018510074A JP2018510074A JP2018537399A5 JP 2018537399 A5 JP2018537399 A5 JP 2018537399A5 JP 2018510074 A JP2018510074 A JP 2018510074A JP 2018510074 A JP2018510074 A JP 2018510074A JP 2018537399 A5 JP2018537399 A5 JP 2018537399A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immunoglobulin
- chain variable
- variable region
- region sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214605P | 2015-09-04 | 2015-09-04 | |
| US62/214,605 | 2015-09-04 | ||
| PCT/US2016/050213 WO2017041001A2 (en) | 2015-09-04 | 2016-09-02 | Insulin immunoglobulin fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537399A JP2018537399A (ja) | 2018-12-20 |
| JP2018537399A5 true JP2018537399A5 (enExample) | 2019-10-03 |
| JP6951825B2 JP6951825B2 (ja) | 2021-10-20 |
Family
ID=58188627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510074A Active JP6951825B2 (ja) | 2015-09-04 | 2016-09-02 | インスリン免疫グロブリン融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10501546B2 (enExample) |
| EP (1) | EP3344278A4 (enExample) |
| JP (1) | JP6951825B2 (enExample) |
| KR (1) | KR20180039726A (enExample) |
| CN (1) | CN108348581B (enExample) |
| AU (1) | AU2016315889A1 (enExample) |
| CA (1) | CA2996716A1 (enExample) |
| HK (1) | HK1258125A1 (enExample) |
| WO (1) | WO2017041001A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6951825B2 (ja) | 2015-09-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | インスリン免疫グロブリン融合タンパク質 |
| CN112584853B (zh) * | 2018-09-12 | 2021-12-10 | 美药星（南京）制药有限公司 | 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法 |
| WO2020072181A1 (en) * | 2018-10-01 | 2020-04-09 | University Of Houston System | Engineered active single-polypeptide chain insulin analogs |
| WO2020083277A1 (zh) * | 2018-10-22 | 2020-04-30 | 上海一宸医药科技有限公司 | 一种双特异性抗体 |
| TW202434620A (zh) * | 2019-07-31 | 2024-09-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| CN111041025B (zh) * | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| CN111744019B (zh) | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| EP4252781A1 (en) * | 2020-11-27 | 2023-10-04 | D&D Pharmatech Inc. | Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto |
| CA3200366A1 (en) * | 2020-11-27 | 2022-06-02 | D&D Pharmatech Inc. | Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto |
| WO2025098472A1 (zh) * | 2023-11-08 | 2025-05-15 | 北京拓界生物医药科技有限公司 | 融合蛋白及其医药用途 |
| WO2025210538A1 (en) * | 2024-04-02 | 2025-10-09 | Biohaven Therapeutics Ltd. | Bifunctional degraders |
| CN118834293B (zh) * | 2024-08-06 | 2025-09-19 | 扬州大学 | 一种基于h5n8亚型禽流感病毒na的单克隆抗体及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| SI1983000T1 (sl) | 2003-11-21 | 2015-12-31 | Ucb Biopharma Sprl | Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17 |
| AU2005203962C1 (en) * | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| JP2008531060A (ja) | 2005-03-04 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法 |
| US20110135725A1 (en) | 2005-05-23 | 2011-06-09 | Sdg, Inc. | Lipid Construct for Delivery of Insulin to a Mammal |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| WO2008047914A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif |
| FR2929509B1 (fr) | 2008-04-02 | 2011-01-21 | Lvmh Rech | L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle. |
| WO2009132129A2 (en) | 2008-04-22 | 2009-10-29 | Case Western Reserve University | Isoform-specific insulin analogues |
| EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| JP2013516967A (ja) * | 2010-01-14 | 2013-05-16 | グラクソ グループ リミテッド | 肝臓標的化ドメイン抗体 |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| UY33578A (es) * | 2010-08-31 | 2012-03-30 | Sanofi Sa | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS |
| WO2013133450A1 (ja) * | 2012-03-06 | 2013-09-12 | 株式会社バイオマトリックス研究所 | がん治療用医薬組成物 |
| US9518112B2 (en) * | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
| US9771427B2 (en) * | 2012-08-09 | 2017-09-26 | Roche Glycart Ag | ASGPR antibodies and uses thereof |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| KR20240154672A (ko) | 2014-02-21 | 2024-10-25 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| PL3129067T3 (pl) | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
| JP6951825B2 (ja) | 2015-09-04 | 2021-10-20 | ザ スクリプス リサーチ インスティテュート | インスリン免疫グロブリン融合タンパク質 |
-
2016
- 2016-09-02 JP JP2018510074A patent/JP6951825B2/ja active Active
- 2016-09-02 AU AU2016315889A patent/AU2016315889A1/en not_active Abandoned
- 2016-09-02 EP EP16843113.8A patent/EP3344278A4/en not_active Withdrawn
- 2016-09-02 HK HK19100415.6A patent/HK1258125A1/zh unknown
- 2016-09-02 CA CA2996716A patent/CA2996716A1/en not_active Abandoned
- 2016-09-02 KR KR1020187008446A patent/KR20180039726A/ko not_active Ceased
- 2016-09-02 US US15/756,296 patent/US10501546B2/en active Active
- 2016-09-02 CN CN201680063883.8A patent/CN108348581B/zh active Active
- 2016-09-02 WO PCT/US2016/050213 patent/WO2017041001A2/en not_active Ceased
-
2019
- 2019-10-24 US US16/663,239 patent/US11421033B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504907A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| WO2016126858A3 (en) | Antibodies directed against lymphocyte activation gene 3 (lag-3) | |
| JP2017048194A5 (enExample) | ||
| JP2019524645A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2016063812A5 (enExample) | ||
| WO2016054598A3 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
| EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
| JP2022553324A5 (enExample) | ||
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| JP2020513804A5 (enExample) | ||
| BR112022009317A2 (pt) | Anticorpos de cd73 biparatópicos | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2017528117A5 (enExample) | ||
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| JP2014237714A5 (enExample) | ||
| EA201791768A1 (ru) | Иммуномодулирующие агенты | |
| WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
| JP2018033454A5 (enExample) | ||
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2016529229A5 (enExample) | ||
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| JP2021500874A5 (enExample) |